1.20Open1.20Pre Close0 Volume1 Open Interest12.50Strike Price0.00Turnover220.53%IV39.23%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry1.20Extrinsic Value100Contract SizeAmericanOptions Type0.4226Delta0.0766Gamma8.20Leverage Ratio-0.0503Theta0.0016Rho3.47Eff Leverage0.0091Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet